Abstract
Nanocarriers are the small molecules with capability of adhering to or pass through the cell membrane and deliver the genes, peptides, growth factors or toxins to living cells. They form an extremely important part of gene delivery and molecular therapeutics. Besides the viral modes of gene delivery, cationic carrier molecules (e.g., liposome and polymers) that form non-covalent complexes with DNA constitute a major class of nanocarriers. Although relatively less efficient than viral systems, cationic carrier molecules have inherent advantage of flexibility and safety. Their derivatives in conjugation with functional molecules such as, peptides, proteins, growth factors and antibodies have been in focus to generate nanocarriers with low toxicity, high stability, high efficiency and cell-specific targeting features. In this chapter, we discuss the use of cell internalizing antibodies against mortalin protein as nanocarriers. Internalizing anti-mortalin antibodies was employed for (i) internalization of nanoparticles (quantum dots, QD) to generate illuminating cells and (ii) gene delivery. Furthermore, cationic polymer polyethylenimine (PEI) and internalizing anti-mortalin antibody complex was shown to enhance the gene delivery specifically to cancer cells and thus enabling the latter to serve as a novel cancer-targeting nanocarrier.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alivisatos AP, Gu W, Larabell C (2005) Quantum dots as cellular probes. Annu Rev Biomed Eng 7:55–76
Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750–763
Arya H, Kaul Z, Wadhwa R, Taira K, Hirano T, Kaul SC (2005) Quantum dots in bio-imaging: Revolution by the small. Biochem Biophys Res Commun 329:1173–1177
Bakalova R, Zhelev Z, Ohba H, Baba Y (2005) Quantum dot-based western blot technology for ultrasensitive detection of tracer proteins. J Am Chem Soc 127:9328–9329
Ballou B, Ernst LA, Waggoner AS (2005) Fluorescence imaging of tumors in vivo. Curr Med Chem 12:795–805
Bentzen EL, Tomlinson ID, Mason J, Gresch P, Warnement MR, Wright D, Sanders-Bush E, Blakely R, Rosenthal SJ (2005) Surface modification to reduce nonspecific binding of quantum dots in live cell assays. Bioconjug Chem 16:1488–1494
Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92:7297–7301
Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC (2005) In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci 88:412–419
Chiu SJ, Ueno NT, Lee RJ (2004) Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 97:357–369
Cussac D, Pichereaux C, Colomba A, Capilla F, Pont F, Gaits-Iacovoni F, Lamant L, Espinos E, Burlet-Schiltz O, Monsarrat B et al (2006) Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 6:3210–3222
Densmore CL, Kleinerman ES, Gautam A, Jia SF, Xu B, Worth LL, Waldrep JC, Fung YK, T’Ang A, Knight V (2001) Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther 8:619–627
Derfus AM, Chan WCW, Bhatia SN (2004) Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 4:11–18
Duan Y, Guan X, Ge J, Quan D, Zhuo Y, Ye H, Shao T (2008) Cationic nano-copolymers mediated IKKbeta targeting siRNA inhibit the proliferation of human Tenon’s capsule fibroblasts in vitro. Mol Vis 14:2616–2628
Dundas SR, Lawrie LC, Rooney PH, Murray GI (2004) Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 205:74–81
Fan H, Leve EW, Scullin C, Gabaldon J, Tallant D, Bunge S, Boyle T, Wilson MC, Brinker CJ (2005) Surfactant-assisted synthesis of water-soluble and biocompatible semiconductor quantum dot micelles. Nano Lett 5:645–648
Fu A, Gu W, Larabell C, Alivisatos AP (2005) Semiconductor nanocrystals for biological imaging. Curr Opin Neurobiol 15:568–575
Gao X, Cui Y, Levenson RM, Chung LW, Nie S (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22:969–976
Gao J, Li B, Li H, Zhang X, Zhang D, Zhao L, Wang C, Fang C, Qian W, Hou S et al (2009) Development and characterization of a fully functional small anti-HER2 antibody. BMB Rep 42:636–641
Gu W, Pellegrino T, Parak WJ, Boudreau R, Le Gros MA, Gerion D, Alivisatos AP, Larabell CA (2005) Quantum-dot-based cell motility assay. Sci STKE 2005:l5
Guillem VM, Tormo M, Revert F, Benet I, Garcia-Conde J, Crespo A, Alino SF (2002) Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines. J Gene Med 4:170–182
Guo W, Lee RL (1999) Receptor-targeted gene delivery via folate-conjugated polyethylenimine. AAPS PharmSci 1:E19
Hanifi A, Fathi MH, Sadeghi HM, Varshosaz J (2010) Mg2 +substituted calcium phosphate nano particles synthesis for non viral gene delivery application. J Mater Sci Mater Med 21:2393–2401
Hasegawa U, Nomura SM, Kaul SC, Hirano T, Akiyoshi K (2005) Nanogel-quantum dot hybrid nanoparticles for live cell imaging. Biochem Biophys Res Commun 331:917–921
Hoshino A, Hanaki K, Suzuki K, Yamamoto K (2004) Applications of T-lymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body. Biochem Biophys Res Commun 314:46–53
Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res 65:8984–8992
Jaiswal JK, Simon SM (2007) Optical monitoring of single cells using quantum dots. Methods Mol Biol 374:93–104
Kaul Z, Yaguchi T, Kaul SC, Hirano T, Wadhwa R, Taira K (2003) Mortalin imaging in normal and cancer cells with quantum dot immuno-conjugates. Cell Res 13:503–507
Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R (2005) Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem. 280:39373–39379
Kaul SC, Deocaris CC, Wadhwa R (2007a) Three faces of mortalin: A housekeeper, guardian and killer. Exp Gerontol 42:263–274
Kaul Z, Yaguchi T, Harada JI, Ikeda Y, Hirano T, Chiura HX, Kaul SC, Wadhwa R (2007b) An antibody-conjugated internalizing quantum dot suitable for long-term live imaging of cells. Biochem Cell Biol 85:133–140
Kunath K, Merdan T, Hegener O, Haberlein H, Kissel T (2003) Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J Gene Med 5:588–599
Lopes de Menezes DE, Pilarski LM, Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320–3330
Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, Wadhwa R, Luk JM (2011) Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ 18:1046–1056
Ma Z, Izumi H, Kanai M, Kabuyama Y, Ahn NG, Fukasawa K (2006) Mortalin controls centrosome duplication via modulating centrosomal localization of p53. Oncogene. 25:5377–5390
Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M (1997) Immunoliposomes bearing polyethyleneglycol-coupled Fab’ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 413:177–180
Mason JN, Tomlinson ID, Rosenthal SJ, Blakely RD (2005) Labeling cell-surface proteins via antibody quantum dot streptavidin conjugates. Methods Mol Biol 303:35–50
Medintz IL, Uyeda HT, Goldman ER, Mattoussi H (2005) Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 4:435–446
Merdan T, Callahan J, Petersen H, Kunath K, Bakowsky U, Kopeckova P, Kissel T, Kopecek J (2003) Pegylated polyethylenimine-Fab’ antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. Bioconjug Chem 14:989–996
Moffatt S, Cristiano RJ (2006) PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells. Int J Pharm 317:10–13
Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, et al (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172–1181
Park JS, Na K, Woo DG, Yang HN, Kim JM, Kim JH, Chung HM, Park KH (2009) Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials 31:124–132
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760
Pilzer D, Saar M, Koya K, Fishelson Z (2010) Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity. Int J Cancer 126:1428–1435
Pinaud F, Michalet X, Bentolila LA, Tsay JM, Doose S, Li JJ, Iyer G, Weiss S (2006) Advances in fluorescence imaging with quantum dot bio-probes. Biomaterials 27:1679–1687
Santra S, Dutta D, Walter GA, Moudgil BM (2005) Fluorescent nanoparticle probes for cancer imaging. Technol Cancer Res Treat 4:593–602
Sapra P, Allen TM (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62:7190–7194
Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW et al (2003) Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 278:7607–7616
Shiota M, Ikeda Y, Kaul Z, Itadani J, Kaul SC, Wadhwa R (2007) Internalizing antibody-based targeted gene delivery for human cancer cells. Hum Gene Ther 18:1153–1160
Silver J, Ou W (2005) Photoactivation of quantum dot fluorescence following endocytosis. Nano Lett 5:1445–1449
Strehblow C, Schuster M, Moritz T, Kirch HC, Opalka B, Petri JB (2005) Monoclonal antibody-polyethyleneimine conjugates targeting Her-2/neu or CD90 allow cell type-specific nonviral gene delivery. J Control Release 102:737–747
Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB (2000) Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 60:6942–6949
Tomlinson ID, Mason JN, Blakely RD, Rosenthal SJ (2005) Peptide-conjugated quantum dots: imaging the angiotensin type 1 receptor in living cells. Methods Mol Biol 303:51–60
Voura EB, Jaiswal JK, Mattoussi H, Simon SM (2004) Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 10:993–998
Vu TQ, Maddipati R, Blute TA, Nehilla BJ, Nusblat L, Desai TA (2005) Peptide-conjugated quantum dots activate neuronal receptors and initiate downstream signaling of neurite growth. Nano Lett 5:603–607
Wadhwa R, Kaul SC, Ikawa Y, Sugimoto Y (1993a) Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype. J Biol Chem 268:6615–6621
Wadhwa R, Kaul SC, Mitsui Y, Sugimoto Y (1993b) Differential subcellular distribution of mortalin in mortal and immortal mouse and human fibroblasts. Exp Cell Res 207:442–448
Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, Maruta H, Kaul SC (2000) Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 60:6818–6821
Wadhwa R, Ando H, Kawasaki H, Taira K, Kaul SC (2003) Targeting mortalin using conventional and RNA-helicase-coupled hammerhead ribozymes. EMBO Rep 4:595–601
Wadhwa R, Takano S, Taira K, Kaul SC (2004) Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J Gene Med 6:439–444
Wadhwa R, Takano S, Kaur K, Aida S, Yaguchi T, Kaul Z, Hirano T, Taira K, Kaul SC (2005) Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. Biochem J 391:185–190
Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddel RR, Kaul SC (2006) Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 118:2973–2980
Wang G, Qiu J, Wang R, Krause A, Boyer JL, Hackett NR, Crystal RG (2010) Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther 17:559–570
Young SH, Rozengurt E (2006) Qdot nanocrystal conjugates conjugated to bombesin or ANG II label the cognate G protein-coupled receptor in living cells. Am J Physiol Cell Physiol 290:C728–732
Zanta MA, Boussif O, Adib A, Behr JP (1997) In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug Chem 8:839–844
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Kaul, Z., Yaguchi, T., Wadhwa, R., Kaul, S.C. (2012). Cell Internalizing Anti-mortalin Antibody as a Nanocarrier. In: Kaul, S., Wadhwa, R. (eds) Mortalin Biology: Life, Stress and Death. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-3027-4_21
Download citation
DOI: https://doi.org/10.1007/978-94-007-3027-4_21
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-3026-7
Online ISBN: 978-94-007-3027-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)